Leukemia, Myeloid D007951

Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Leukemia » Leukemia, Myeloid

Description

Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.   MeSH

Subtype Terms (7)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
245 drugs (126 approved, 119 experimental)

Leukemia, Myeloid, Acute
871 drugs (240 approved, 631 experimental)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
128 drugs (98 approved, 30 experimental)

Leukemia, Myelomonocytic, Acute
69 drugs (46 approved, 23 experimental)

Leukemia, Myelomonocytic, Chronic
199 drugs (112 approved, 87 experimental)

Leukemia, Myelomonocytic, Juvenile
55 drugs (36 approved, 19 experimental)

Sarcoma, Myeloid
35 drugs (28 approved, 7 experimental)



Organization Involved with Phase 3 Indications (202)

Organization Involved with Phase 2 Indications (358)

Abiogen Pharma

ADC Therapeutics SARL

Agenus Inc.

Akinion Pharmaceuticals AB

ALFA cooperative Group

Ambit Biosciences

Amgen

AnorMED

AOP Orphan Pharmaceuticals AG

Apices Soluciones S.L.

Aprea Therapeutics AB

Aptose Biosciences Inc.

argenx

Array BioPharma

Ascentage Pharma Group Inc.

Aslan Pharmaceuticals

Assisi Foundation

Associazione Italiana per la Ricerca sul Cancro

Asterias Biotherapeutics

Australasian Leukaemia and Lymphoma Group

AVEO Pharmaceuticals

Azienda Ospedaliera Universitaria Senese

AZ Sint-Jan

Bayer

Baylor University

Beat AML

Bellicum Pharmaceuticals

Ben Gurion University

BerGenBio ASA

Bio-Cancer Treatment International Limited

Biodesix Inc.

Bioenvision

BioLineRx, Ltd.

BioMAS Ltd

BioMed Valley Discoveries, Inc

Bio-Path Holdings, Inc.

BioSight Ltd.

Biosuccess Biotech Co., Ltd.

BreakThrough Therapeutics

Brown University

Cancer Insight, LLC

Cancer Trials Ireland

Cantex Pharmaceuticals

Cardiff Oncology

Case Western Reserve University

Celldex Therapeutics

Cellerant Therapeutics

Cell Genesys

Cellgenix

Cell Therapy Catapult

Centre Leon Berard

Chao Family Comprehensive Cancer Center

ChemGenex Pharmaceuticals

Children's National Medical Center

Chonbuk National University

Chongqing Medical University

Chongqing Precision Biotech Co., Ltd

Chonnam National University

Chroma Therapeutics

Chu De Liège

CHU Henri Mondor

CHU Mont-Godinne

Chung-Ang University

City of Hope National Medical Center

Clear Creek Bio, Inc.

Clinica Universidad de Navarra

Clinique Charcot

Colorado Blood Cancer Institute

Columbia University

CTI BioPharma

Cure CML Consortium

Curie Institute

Daegu Catholic University

Data Matrix, LTD

DCPrime BV

Department of Health and Human Services

Department of Health, United Kingdom

Department of Veteran Affairs

Doris Duke Charitable Foundation

Dutch Cancer Society

East Carolina University

ECOG-ACRIN Cancer Research Group

Eleos, Inc.

Emory University

Epidemiological and Clinical Research Information Network

ERYtech Pharma

European Commission

European Group for Blood and Marrow Transplantation

European LeukemiaNet

Ewha Womans University

Exelixis

F2G Ltd.

Federal University of Health Science of Porto Alegre

Federal University of Rio Grande do Sul

Fondation ARC

Forma Therapeutics, Inc.

Fortress Biotech

Free University of Amsterdam

Free University of Brussels

Froedtert Memorial Lutheran Hospital

Fujifilm

Fundacion CRIS de Investigación para Vencer el Cáncer

Fundación Teófilo Hernando, Spain

Fundació Sant Joan de Déu

Fusion Pharma LLC

Genta

Georgetown University

Gilead Sciences

GlaxoSmithKline

Glycostem Therapeutics BV

GOELAMS Cooperative Group

Golden Biotechnology Corp.

Government of China

Government of Italy

Government of Korea

Government of Singapore

Government of Spain

Groupe Francophone des Myelodysplasies

Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias

GWT-TUD GmbH

Hanmi Pharmaceutical

Hannover Clinical Trial Center GmbH

Hannover Medical School

Hanyang University

Hefei University

Hematologics, Inc

Hengrui Therapeutics, Inc.

Herbert Irving Comprehensive Cancer Center

Hikma

Hôpital Mignot, Versailles Paris

Hopital Rene Huguenin_Intitut Curie_Paris

Hospital Infantil Universitario Niño Jesús, Madrid, Spain

Hospital La Paz

Hospital San Pedro de Alcantara

Hospital Santa Marcelina, Sao Paulo, Brasil

Hospital Universitario Ramon y Cajal

Huazhong University of Science and Technology

Humboldt University

Hybrigenics

ICON

I-Mab Biopharma

Immune System Key Ltd

ImmunogenX

INC Research

Incyte

Inha University

Innate Pharma

Innovative Therapies For Children with Cancer Consortium

Innovent Biologics (Suzhou) Co. Ltd.

Institut Paoli-Calmettes

inVentiv

IQVIA

Istituto Nazionale per lo Studio e la Cura dei Tumori

Janssen Pharmaceutica NV

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Jin Yang Pharmaceutical

Julius-Maximilians University

Kanto CML Study Group

Karolinska Institute

Kartos Therapeutics, Inc.

Karyopharm Therapeutics Inc

Katholieke Universiteit Leuven

Keimyung University

Keio University

Klinik Hirslanden, Zurich

Konkuk University

Korea Research Institute of Bioscience and Biotechnology

Leiden University

Leo W. Jenkins Cancer Center

Lund University

Luoyang Central Hospital

MaaT Pharma

Mario Negri Institute

Marker Therapeutics

Mateon Therapeutics

Mayo Clinic

McGill University

Medac

Medical University of South Carolina

MediGene

MedImmune

Medivation

Memorial Sloan-Kettering Cancer Center

Merck KGaA

Merck Serono

Methodist Cancer Center, Houston, Texas

MethylGene Inc.

Miltenyi Biotec, Inc.

Mirati Therapeutics Inc.

Moleculin, LLC

MolMed S.p.A.

Monash University

Monter Cancer Center

Moorgreen Hospital, Southampton

MultiPharma

National Hospital Organization, Mito Medical Center

National Institutes of Health (NIH)

NewLink Genetics Inc

New Mexico Cancer Care Alliance

New York Medical College

New York University

Nippon Medical School

Nohla Therapeutics, Inc.

North Shore Hospital, New Zealand

Northside Hospital, Inc.

Norwegian University of Science and Technology

OBiS, Inc

OCT Clinical Trials

Ohio State University

OHSU Knight Cancer Institute

OncoEthix

Onconova Therapeutics, Inc.

OncoTherapy Science, Inc.

Onxeo

Oregon Health and Science University

Oshadi Drug Administration

Ospedale Sant' Eugenio

Otsuka

Paris Diderot University

Pavlov First Saint Petersburg State Medical University

Pennsylvania State University

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Peter MacCallum Cancer Centre

Pharmacyclics

Philipps University of Marburg

Plexxikon

Polaris Group

PPD

PrECOG, LLC.

Prism Research

Proacta, Incorporated

Q2 solutions

Race Oncology Ltd

Renato Melaragno

Rhode Island Hospital

Rocky Mountain Cancer Centers - Denver Midtown

Royal Marsden Hospital NHS Trust

Rush University

RWTH Aachen University

S*BIO

Schering-Plough

SCRI Development Innovations

Selvita S.A.

Servier

SGX Pharmaceuticals

Shanghai institute of Hematology

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Sheba Medical Center

Shenzhen Geno-Immune Medical Institute

Shijiazhuang Pharma Group (CSPC)

Shimousa Hematology Study Group

Shire

Singapore General Hospital

SPARC

Spectrum Pharmaceuticals

Spedali Civili di Brescia

Spirogen

State of Texas

St. Baldrick's Foundation

Stemline Therapeutics, Inc.

Sumitomo

Sungkyunkwan University

Suzhou Yasheng Pharmaceutical Co., Ltd

Swiss Group for Clinical Cancer Research

Symphony Capital

Synimmune GmbH

Syntax for Science

Syros Pharmaceuticals

Takeda

Technical University of Munich

Telios Pharma, Inc.

Texas Oncology Cancer Center

The Cleveland Clinic

The EMMES Corporation

The First People's Hospital of Yunan Province

The Foundation Institute San Raffaele G. Giglio of Cefalù

The Korean Society of Blood and Marrow Transplantation

The Korean Society of Hematology

The Korean Society of Pediatric Hematology Oncology

Theradex

The University of Hong Kong

The University of Texas, Dallas

Thomas Jefferson University

Tokyo Metropolitan Komagome Hospital

Tolero Pharmaceuticals

Tufts University

Universidad Autonoma de Madrid

Universita' Cattolica del Sacro Cuore

Universitair Ziekenhuis Gent

Université catholique de Louvain

University Hospital Brno

University Hospital of Mont-Godinne

University Hospital of North Norway

University of Alabama, Birmingham

University of Antwerp

University of Arizona

University of Bergen

University of Bern

University of Bonn

University of California, Davis

University of California, San Diego

University of California, San Francisco

University of Campinas

University of Cincinnati

University of Colorado, Denver

University of Copenhagen

University of Duesseldorf

University of Duisburg-Essen

University of Erlangen-Nuremberg

University of Geneva

University of Helsinki

University of Iowa

University of Kentucky

University of Lausanne

University of Lille

University of Liverpool

University of Lorraine

University of Malaga

University of Maryland

University of Medicine and Dentistry of New Jersey

University of Melbourne

University of Miami

University of Michigan

University of Milan

University of Minnesota

University of Montreal

University of Nebraska

University of New Mexico

University of North Carolina at Chapel Hill

University of Oslo

University of Regensburg

University of Rochester

University of Roma La Sapienza

University of Rostock

University of Salamanca

University of Seville

University of Southern California

University of Southern Denmark

University of South Florida

University of Stavanger

University of Toronto

University of Tuebingen

University of Wisconsin

Uppsala University

Vanderbilt University

Vical

Virginia Commonwealth University

Vita-Salute University of Milano. Italy

Wake Forest University

Washington University in St. Louis

Wayne State University

Xanthus Pharmaceuticals, Inc.

Xiamen University

Yale University

Yeshiva University

Yonsei University

Zhengzhou University

ZNA Antwerpen

Organization Involved with Phase 1 Indications (125)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.